GLP-1 & Incretin Science

Tirzepatide Has No Active Comparator in the Network

UKPWritten and published by UK Peptides4 min readUpdated 7 cited sources

The short answer

A network meta-analysis is only as good as the links between its trials. In the 2026 obesity network, tirzepatide connects to semaglutide and liraglutide entirely through placebo arms, and more than half the participants come from a single trial published in 2015.

Key facts

Network
Ciudin et al., Adv Ther 2026 (PMID 41820778)
Trials in network
6
Total tabulated participants
9,355
Trials with an active comparator
2 (O'Neil 2018, STEP 8)
Active-comparator link
Semaglutide vs liraglutide only
Tirzepatide trials in network
1 (SURMOUNT-1, placebo-controlled)
Largest contributor
SCALE Obesity and Prediabetes, 4,974 tabulated
Publication years spanned
2015 to 2022

Draw the network before reading the result

Every network meta-analysis has a shape, and the shape carries more information than the headline estimate. In this one, six trials connect three drugs. SURMOUNT-1 randomised tirzepatide against placebo. STEP 1 and STEP 5 randomised semaglutide against placebo. SCALE Obesity and Prediabetes randomised liraglutide against placebo. Two trials, the O'Neil 2018 dose-ranging study and STEP 8, randomised semaglutide directly against liraglutide. Add those up and one fact stands out: there is no trial anywhere in this network in which tirzepatide is randomised against an active drug.

What that means for the tirzepatide comparisons

Every estimate of tirzepatide against semaglutide, and of tirzepatide against liraglutide, is produced by comparing SURMOUNT-1's placebo arm with the placebo arms of the semaglutide and liraglutide trials, and assuming those placebo arms are exchangeable. That assumption is called transitivity, and it carries the whole load. It is not obviously wrong here, since all six trials enrolled adults without type 2 diabetes on a background of reduced-calorie diet and increased physical activity, with similar baseline weight and BMI. But it is an assumption about unobserved comparability, and no amount of statistical machinery can test it directly.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The two active-comparator trials contribute 239 and 338 participants in the analysis's own tabulation, 577 people out of 9,355. Everything the network says about how semaglutide and liraglutide compare is anchored, in part, on those 577. STEP 8 is also the one trial the authors flag as different in design: it was double-blind between each treatment and its matched placebo but not between the active treatments, because their dosing schedules differ, and it ran in a single country. Small, partially blinded, single-country trials are not disqualifying, but it is useful to know that one sits at the join.

More than half the network is one trial from 2015

SCALE Obesity and Prediabetes contributes 4,974 of the 9,355 tabulated participants (53% of the network), and it is the sole anchor for liraglutide. It was published in 2015, seven years before SURMOUNT-1, STEP 5 and STEP 8. Trial vintage matters more than it looks. Background care changes, participant expectations change, and analytical conventions change: the SCALE report used last-observation-carried-forward imputation, a method largely superseded by the estimand framework that the later trials use. The authors note that SCALE Obesity and Prediabetes is the one study in the network that did not report an efficacy estimand at all, which is a substantive gap given that the efficacy estimand is where the headline comparisons against liraglutide come from.

A sample size that does not match the registry

The analysis tabulates 4,974 participants for SCALE Obesity and Prediabetes. The trial's registry record, NCT01272219, records 3,731 as actual enrolment, and the New England Journal report describes 3,731 patients randomised in a 2:1 ratio to liraglutide 3.0 mg or placebo over 56 weeks. The two figures differ by more than a thousand people and the text available does not explain the difference; a plausible reading is that the analysis counts a broader population than the 56-week randomised phase, but that is inference, not something the paper states. Anyone relying on this network should check it against the supplementary material. The O'Neil figure moves the other way (239 tabulated against 957 randomised in NCT02453711), which is straightforwardly explained by a dose-ranging trial contributing only the arms relevant to the network.

How to use any of this

None of it makes the analysis wrong. It makes the analysis legible, which is different and more useful. When a network estimate is quoted at you, three questions get you most of the way: which trials are actually in it, where the direct evidence sits, and whether the drug you care about is connected to anything except placebo. In this network the answers are six, in two small trials on the semaglutide-liraglutide edge, and no.

Frequently asked questions

Is a placebo-anchored comparison worthless?

No. It is how most indirect comparison works and it can be accurate. In this very network the placebo-anchored tirzepatide-versus-semaglutide estimate was later matched to within a quarter of a percentage point by a head-to-head trial. The issue is that its accuracy depends on an assumption you should know is being made, not that it fails.

What would break transitivity here?

Any factor that differs systematically between the trials and also modifies treatment effect. Different eras of background lifestyle support, different baseline severity, different rates of discontinuation, or different definitions of the analysis population would all do it. Comparing placebo arms across the trials is the usual informal check.

Why does the number of trials in a network matter?

Because a sparse network has few redundant paths, so there is little opportunity to check whether direct and indirect evidence agree. With six trials and only one active-comparator edge, this network has almost no capacity for that internal consistency check.

Does this apply to other network meta-analyses?

The structural questions do. Sparse networks anchored on placebo, dominated by one large old trial, with a single small bridge between two of the drugs, are common across therapeutic areas. Reading the network diagram before the forest plot is a general habit worth having.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.